Leqembi (lecanemab) is an amyloid beta-directed antibody used for Alzheimer’s disease (AD). Treatment should be initiated in those with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was started in clinical trials. Recommended Dosage: The recommended dosage of Leqembi injection is 10 mg per kg which must be diluted and then administered as an intravenous (IV) infusion over around 60 minutes, once every two weeks. In case an infusion is skipped or missed, administer the very next scheduled dose as promptly as possible.
